A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD, SINGLE-DOSE, CROSS-OVER STUDY TO ESTIMATE THE ABSOLUTE BIOAVAILABILITY OF VEPDEGESTRANT (ARV-471, PF-07850327) FOLLOWING ORAL AND INTRAVENOUS DOSING OF THE DRUG TO HEALTHY PARTICIPANTS
Latest Information Update: 07 Jul 2025
At a glance
- Drugs Vepdegestrant (Primary) ; Vepdegestrant (Primary)
- Indications HER2 negative breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 29 Jun 2025 Status changed from recruiting to completed.
- 11 May 2025 Status changed from not yet recruiting to recruiting.
- 09 Apr 2025 New trial record